Literature DB >> 19780936

The impact of the prevention programme of hepatitis C over more than a decade: the French experience.

E Delarocque-Astagneau1, C Meffre, F Dubois, C Pioche, Y Le Strat, F Roudot-Thoraval, P Hillon, C Silvain, D Dhumeaux, J-C Desenclos.   

Abstract

To assess the impact of the French national hepatitis C prevention programme initiated in 1999, we analysed trends in hepatitis C virus (HCV) prevalence, testing and characteristics of HCV-infected patient at first referral from 1994 to 2006. We used four data sources: Two national population-based sero-prevalence surveys carried out in 1994 and 2004; two surveillance networks, one based on public and private laboratories throughout France and the other on hepatology reference centres, which aim to monitor, respectively, trends of anti-HCV screening and of epidemiological-clinical characteristics of HCV patients at first referral. Between 1994 and 2004, the anti-HCV prevalence for adults aged 20-59 years decreased from 1.05 (95% confidence interval 0.75-1.34) to 0.71 (0.52-0.97). During the same period, those anti-HCV positive with detectable HCV RNA decreased from 81 to 57%, whereas, the proportion of anti-HCV positive persons aware of their status evolved from 24 to 56%. Anti-HCV screening activity increased by 45% from 2000 to 2005, but decreased in 2006 (-10%), while HCV positivity among those tested decreased from 4.3 to 2.9%. The proportion of cirrhosis at first referral remains around 10% between 2001 and 2006, with many patients with excessive alcohol consumption (34.7% among males) or viral co-infections (HIV seropositivity for 5.2% patients). Our analysis indicates that the national programme had a positive impact at the population level through improved prevention, screening and management. There is still a need to identify timely those at risk for earlier interventions, to assess co-morbidities better and for a multidisciplinary approach to HCV management.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19780936     DOI: 10.1111/j.1365-2893.2009.01196.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  16 in total

Review 1.  Barriers to hepatitis C treatment.

Authors:  Christopher E McGowan; Michael W Fried
Journal:  Liver Int       Date:  2012-02       Impact factor: 5.828

2.  Hepatocellular carcinoma: prevention and therapy.

Authors:  Davendra P S Sohal; Weijing Sun
Journal:  Curr Oncol Rep       Date:  2011-06       Impact factor: 5.075

Review 3.  Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?

Authors:  Andrew J Muir; Susanna Naggie
Journal:  Clin Gastroenterol Hepatol       Date:  2015-07-17       Impact factor: 11.382

Review 4.  Best strategies for global HCV eradication.

Authors:  Liesl M Hagan; Raymond F Schinazi
Journal:  Liver Int       Date:  2013-02       Impact factor: 5.828

Review 5.  Epidemiology and natural history of HCV infection.

Authors:  Behzad Hajarizadeh; Jason Grebely; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-02       Impact factor: 46.802

Review 6.  Hepatitis C virus prevalence and genotype distribution in Pakistan: Comprehensive review of recent data.

Authors:  Muhammad Umer; Mazhar Iqbal
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

7.  The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014.

Authors:  Cécile Brouard; Yann Le Strat; Christine Larsen; Marie Jauffret-Roustide; Florence Lot; Josiane Pillonel
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

8.  Improved hepatitis C screening and treatment in people who inject drugs should be a priority in Europe.

Authors:  Achim Kautz; Lilyana Chavdarova; Margaret Walker
Journal:  BMC Infect Dis       Date:  2014-09-19       Impact factor: 3.090

9.  High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening analysis of 28,809 patients.

Authors:  Johannes Vermehren; Beate Schlosser; Diana Domke; Sandra Elanjimattom; Christian Müller; Gudrun Hintereder; Karin Hensel-Wiegel; Rudolf Tauber; Annemarie Berger; Norbert Haas; Felix Walcher; Martin Möckel; Ralf Lehmann; Stefan Zeuzem; Christoph Sarrazin; Thomas Berg
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

10.  Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study.

Authors:  Leila M M B Pereira; Celina M T Martelli; Regina C Moreira; Edgar Merchan-Hamman; Airton T Stein; Maria Regina A Cardoso; Gerusa M Figueiredo; Ulisses R Montarroyos; Cynthia Braga; Marília D Turchi; Gabriela Coral; Deborah Crespo; Maria Luiza C Lima; Luis Claudio A Alencar; Marcelo Costa; Alex A dos Santos; Ricardo A A Ximenes
Journal:  BMC Infect Dis       Date:  2013-02-01       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.